Eli Lilly and Company (NYSE:LLY) is among the stocks with the best earnings growth for the next 5 years. On January 14, BMO Capital reaffirmed an ‘Outperform’ rating on Eli Lilly and Company (NYSE:LLY ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

What's encouraging, however, is that there may be more benefits with GLP-1 drugs than simply losing weight and controlling ...

Humana’s CenterWell pharmacy will dispense GLP-1 weight loss drugs made by Eli Lilly as part of a new program for employers ...

Before that, Eli Lilly launched TuneLab, a platform for an AI drug-discovery model, which it made available to smaller biotechs that wouldn't otherwise be able to build one. Access to the platform is ...

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" start after its launch this month, analysts said on Friday ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.

France's Finance ​Ministry said on Monday it had received no formal request for investment approval ‌regarding French biotech ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...